ABCL — AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ Global Select
- Employees: 596
- Website: https://www.abcellera.com
Latest SEC filings for ABCL
- 424B5 — 2026-08-13
- 424B5 — 2026-08-13
- 8-K — 2026-08-13
- 424B5 — 2026-08-11
- 424B5 — 2026-08-11
- 8-K — 2026-08-10
- 8-K — 2026-08-07
- 10-Q — 2026-08-05
- 8-K — 2026-08-05
- 8-K — 2026-07-29
Latest ABCL news
- — Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera (GlobeNewswire Inc.)
- — AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting (businesswire.com)
- — AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 (businesswire.com)
- — AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts
Educational tool only — not investment advice.